CBC, or cannabichromene, is one of the major cannabinoids produced by the cannabis plant, and it won’t get you high. Unlike THC, CBC has very weak binding affinity for the CB1 receptors in your brain that produce a psychoactive effect. Instead, it works through a completely different set of pathways in the body, activating pain and temperature receptors that influence inflammation, pain signaling, and even skin health.
How CBC Differs From THC and CBD
All cannabinoids in the cannabis plant start from the same precursor molecule, CBGA, sometimes called the “mother cannabinoid.” Specific enzymes convert CBGA into different cannabinoid acids. The enzyme CBCA synthase converts CBGA into CBCA, which then becomes CBC when exposed to heat or light. This is the same general process that produces THC and CBD, just with a different enzyme driving the conversion.
CBC is classified as non-psychoactive. Where THC locks directly into the CB1 receptor in your brain to produce its signature high, CBC largely bypasses that receptor. Instead, it interacts with a family of ion channels called TRP channels, which are embedded throughout your body and play roles in pain perception, temperature sensing, and inflammation. CBC is a potent activator of TRPA1 (a channel involved in pain and inflammatory signaling) and also activates TRPV1, TRPV3, and TRPV4. It blocks TRPM8, a channel associated with cold sensation. This receptor profile gives CBC a distinct set of effects that have nothing to do with feeling intoxicated.
Pain Relief
CBC’s strongest research support so far is in pain reduction. In a 2024 study published in Biomedicines, researchers tested CBC on mice with nerve pain and found it significantly reduced mechanical sensitivity at doses of 10 and 20 mg/kg, with effects peaking one to two hours after treatment. The pain relief was comparable to indomethacin, a standard anti-inflammatory painkiller, with no statistically significant difference between the two in either male or female mice.
The study tested multiple types of pain. In a formalin test, which measures both acute pain (phase 1) and inflammatory pain (phase 2), CBC significantly reduced pain behaviors in both phases. It also increased pain tolerance in a tail-flick test, which measures response to heat. These results held across both sexes, suggesting CBC’s analgesic effects aren’t limited to one type of pain or one biological context.
CBC’s pain-relieving action likely comes from its activation of TRPA1 and its activity at the CB2 receptor, which is found primarily in immune cells and peripheral tissues rather than the brain. This means it may reduce pain through anti-inflammatory pathways without the cognitive side effects associated with THC.
Anti-Inflammatory Properties
Inflammation is closely tied to CBC’s pain effects, but it extends further. CBC has been reported to have both anti-inflammatory and antimicrobial activity. Its activation of TRP channels plays a role here: TRPA1, which CBC activates with high potency (an EC50 of just 0.09 µM, meaning it takes very little CBC to trigger the receptor), is deeply involved in the body’s inflammatory response. By engaging these channels, CBC appears to modulate how the immune system reacts to injury or irritation.
This anti-inflammatory action is part of why researchers have explored CBC for skin conditions and gut inflammation, not just pain. The cannabinoid seems to dial down the overactive immune signaling that drives chronic inflammatory problems.
Effects on Brain Cell Health
One of the more intriguing findings about CBC involves neural stem cells, the precursor cells that can develop into new brain cells. A study published in the journal Neurochemistry International found that CBC increased the viability of mouse neural stem and progenitor cells during differentiation. At a concentration of 1 µM, CBC helped these cells survive while preventing them from turning into astroglia, a type of support cell in the brain that, when overproduced, can contribute to neurological problems.
The mechanism appears to involve adenosine signaling. CBC raised ATP levels in the stem cells, which acts as a marker for adenosine activity. When researchers blocked the adenosine A1 receptor, CBC’s effects on a key survival pathway (ERK1/2 phosphorylation) and on the stem cell marker nestin were both counteracted. This suggests CBC supports neural stem cell survival through a specific biochemical route rather than a general protective effect. The practical implications for humans aren’t established yet, but the finding positions CBC as a cannabinoid of interest for brain health research.
Skin and Acne
CBC also shows promise for skin conditions, particularly acne. Acne is driven in part by overactive sebum production in the skin’s oil glands. Research on human sebocytes (the cells that produce sebum) found that CBC inhibited both normal lipid synthesis and the exaggerated, “acne-like” lipid production triggered by arachidonic acid, an inflammatory compound.
CBC displayed what researchers called “significant lipostatic activity,” meaning it actively suppressed fat production in these skin cells. It also showed anti-inflammatory properties in the same skin cell models. At very high concentrations (50 µM and above), CBC could even induce cell death in sebocytes, though that level is well above what topical products would typically deliver. The combination of reduced oil production and reduced inflammation makes CBC a candidate for acne management, though human clinical trials are still needed to confirm what the cell studies suggest.
How CBC Works With Other Cannabinoids
CBC is often discussed in the context of the “entourage effect,” the idea that cannabinoids work better together than in isolation. Because CBC operates through TRP channels and CB2 receptors rather than CB1, it complements THC and CBD rather than competing with them. A cannabis strain or product containing CBC alongside other cannabinoids may produce a broader range of effects than one relying on THC or CBD alone.
CBC is typically found in smaller quantities than THC or CBD in most cannabis strains, which is why it’s sometimes called a “minor cannabinoid.” However, breeding and extraction techniques have made CBC-enriched products more available. You’ll find it in some full-spectrum cannabis oils, tinctures, and concentrates marketed for pain or inflammation. Because it’s non-psychoactive, it’s also appearing in topical products aimed at skin health.